Oxford Immunotec Global PLC Announces Pricing of Initial Public Offering
Oxford Immunotec Global PLC (NASDAQ: OXFD) (the “Company”) announced today that its initial public offering of 5,360,000 ordinary shares priced at $12.00 per share. The Company has granted the underwriters the option to purchase up to an additional 804,000 ordinary shares at the initial public offering price less the underwriting discount. The ordinary shares are expected to begin trading on The NASDAQ Global Market on November 22, 2013 under the trading symbol “OXFD.”
J.P. Morgan Securities LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Cowen and Company, LLC and Robert W. Baird & Co. Incorporated are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 21, 2013. When available, copies of the final prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (866) 803-9204, or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402 or by telephone at (800) 747-3924, or by e-mailing a request to prospectus@pjc.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Notes to Editors:
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Its proprietary T-SPOT technology platform allows it to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human body’s immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, cancers and autoimmune diseases. Oxford Immunotec Global PLC is headquartered near Oxford, UK and in Marlborough, MA.
Website: www.oxfordimmunotec.com
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
Contacts
Oxford Immunotec Global PLC
Media Relations
Beth Elkins
+44 1235 442780
belkins@oxfordimmunotec.com
or
Investor Relations
Richard M. Altieri
Chief Financial Officer
508-481-4648
Raltieri@oxfordimmunotec.com
Help employers find you! Check out all the jobs and post your resume.
